Injective price has seen a significant surge of over 17% as the broader crypto market continues to climb higher. This rally has been fueled by a combination of fresh institutional developments and ecosystem enhancements that have added momentum to Injective’s growth. One of the key developments contributing to this surge is the update from 21Shares regarding their proposed Injective ETF.
In their latest filing update, 21Shares has outlined a staking strategy for their Injective investment product. The ETF aims to stake between 40% and 60% of its INJ holdings, with the flexibility to adjust this allocation based on liquidity requirements. This staking structure could potentially generate additional yield for the fund while also allowing for effective liquidity management. The proposed ETF is expected to pursue a Nasdaq listing under the ticker TINJ, with the FTSE Injective Index serving as its pricing benchmark. BNY Mellon has been named as the administrator, transfer agent, and cash custodian for the ETF.
The integration of Injective with Phantom is another significant development that has expanded the accessibility of INJ tokens. This integration enables users to hold, trade, borrow, and exchange tokens through Phantom’s application and web extension. By tapping into Phantom’s established presence in the Solana ecosystem, Injective is able to reach a wider audience beyond its native user base. This integration aligns with Injective’s focus on financial infrastructure, cross-chain accessibility, and tokenized assets.
The 17% rally in INJ price reflects the positive market sentiment surrounding the ETF filing and Phantom integration. However, for this rally to sustain, there needs to be continued buying pressure and support from the broader market. Traders should monitor the volume and market activity to gauge the sustainability of the rally. While the recent developments have strengthened Injective’s narrative, price confirmation and ongoing participation are crucial for a durable trend reversal.
Looking ahead, the latest developments from Injective have bolstered its market narrative, with potential institutional exposure through the ETF and enhanced accessibility through Phantom. The staking component of the ETF and the wallet integration may further support wider ecosystem participation. However, the long-term impact will depend on regulatory progress, user adoption, and sustained demand for INJ. The current rally reflects a renewed market focus, but sustained strength will require more than just announcement-driven momentum.